We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Opana ER

News List

Impax in hot water for 'pay-for-delay' deal on Endo painkiller Opana ER, feds say fiercepharma
April 02, 2019
The Federal Trade Commission has been cracking down on “pay-for-delay" deals across pharma, and Impax ……
Struggling Endo's write-downs pass $5B for 2017 thanks to Opana, mesh, restructuring fiercepharma
August 09, 2017
In Feburary 2017, Endo took a huge $3.5 billion write-down—but that wouldn’t be just it for the year.
FDA Requests Removal of Opana ER for Risks Related To Abuse americanpharmaceuticalreview
June 12, 2017
The U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concer